The success of cancer therapies is hampered by a paucity of suitable drug targets and the rapid development of therapy resistance. The concept of synthetic lethality provides a potential solution to these constraints via the identification of novel therapeutic vulnerabilities, as exemplified in two recent studies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy
Nature Communications Open Access 07 April 2022
-
WDHD1 is essential for the survival of PTEN-inactive triple-negative breast cancer
Cell Death & Disease Open Access 21 November 2020
-
Blocking HIF signaling via novel inhibitors of CA9 and APE1/Ref-1 dramatically affects pancreatic cancer cell survival
Scientific Reports Open Access 13 September 2018
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Weinstein, I. B. Addiction to oncogenes — the Achilles heal of cancer. Science 297, 63–64 (2002).
Hochhaus, A. et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N. Engl. J. Med. 376, 917–927 (2017).
Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005).
Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).
Zhao, D. et al. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature 542, 484–488 (2017).
Solimini, N. L., Luo, J. & Elledge, S. J. Non-oncogene addiction and the stress phenotype of cancer cells. Cell 130, 986–988 (2007).
Wang, T. et al. Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic Ras. Cell 168, 890–903 (2017).
Prahallad, A. et al. Unresponsiveness of colon cancer to BRAFV600E inhibition through feedback activation of EGFR. Nature 483, 100–103 (2012).
Prahallad, A. & Bernards, R. Opportunities and challenges provided by crosstalk between signalling pathways in cancer. Oncogene 35, 1073–1079 (2016).
Kopetz, S. et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer [abstract]. J. Clin. Oncol. 35, 520 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Brunen, D., Bernards, R. Exploiting synthetic lethality to improve cancer therapy. Nat Rev Clin Oncol 14, 331–332 (2017). https://doi.org/10.1038/nrclinonc.2017.46
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.46
This article is cited by
-
Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy
Nature Communications (2022)
-
WDHD1 is essential for the survival of PTEN-inactive triple-negative breast cancer
Cell Death & Disease (2020)
-
Blocking HIF signaling via novel inhibitors of CA9 and APE1/Ref-1 dramatically affects pancreatic cancer cell survival
Scientific Reports (2018)
